AstraZeneca pauses $270 million investment in Britain

Keir Starmer suffers hit to economic plans after AstraZeneca ends £200m investment in Cambridge research site

Britain's largest drug-maker AstraZeneca has halted the £200million investment into its Cambridge research site in a hit to Sir Keir Starmer's economic plans

AstraZeneca pauses £200m expansion in Cambridge

It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year.

AstraZeneca pauses £200m Cambridge investment

Its decision comes as the industry says there is a lack of government investment and as the US pressures firms to invest there.

AstraZeneca pauses £200m expansion of its Cambridge headquarters

The drugmaker has dealt another blow to the government’s life sciences strategy, having already scrapped a £450m expansion of its vaccine plant in Liverpool

AstraZeneca follows Merck’s pullback in Britain (AZN:NASDAQ)

AstraZeneca (AZN) stock is in focus as the company pauses a £200M investment in Britain following a similar move by Merck (MRK). Read more here.

AstraZeneca Halts Investment Amid UK Pharma Challenges

AstraZeneca has paused a significant £200 million investment in its Cambridge research site, impacting planned job creation. This follows the abandonment of a £450 million investment in northern England and highlights wider concerns about the UK's business climate for pharmaceutical companies.